Esperion Logo (primary).png
NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
October 07, 2020 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were presented at the virtual 88th Annual...
Orringer, Carl
ACC, AHA Release 2018 Guideline on the Management of Blood Cholesterol at AHA Scientific Sessions
November 10, 2018 12:55 ET | National Lipid Association
NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease CHICAGO, Nov. 10, 2018 (GLOBE NEWSWIRE) -- The American College of...
NLA LOGO - USE.png
PCSK9 Barriers Survey Results Revealed at National Lipid Association Conference
February 07, 2017 09:30 ET | National Lipid Association
PHOENIX, AZ--(Marketwired - February 07, 2017) - As part of its Spring Clinical Lipid Update (CLU) in Phoenix, the National Lipid Association (NLA) will reveal the results of its "Challenges in...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
September 24, 2014 09:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
September 24, 2013 08:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...